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Abstract 
 
Background 
Although there are recommendations for the management of osteoarthritis (OA), little 
is known about how people with OA actually manage this chronic condition. 
Purpose 
The aims of this study were to identify the non-pharmacological and pharmacological 
therapies most commonly used for the management of hip or knee OA, in a 
community-based sample of adults, and to compare these with evidence-based 
recommendations. 
Methods 
A questionnaire was mailed to 2200 adult members of Arthritis Queensland living in 
Brisbane, Australia. It included questions about OA symptoms, management 
therapies and demographic characteristics.   
Results 
Of the 485 participants (192 men, 293 women) with hip or knee OA who completed 
the questionnaire, most had mild to moderate symptoms. Ninety-six percent of 
participants (aged 27–95 years) reported using at least one non-pharmacological 
therapy, and 78% reported using at least one pharmacological therapy. The most 
common currently used non-pharmacological strategy was range-of-motion 
exercises (men 52%, women 61%, p=0.05) and the most common frequently used 
pharmacological strategy was glucosamine/chondroitin (men 51%, women 60%, ns). 
For the most highly recommended strategies, 65% of men and 54% of women had 
never attended an information/education course (p=0.04), and fewer than half (46% 
of women and 42% of men, p=0.03) were frequent users of anti-inflammatory agents.  
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Conclusion 
The findings suggest that many people with knee or hip OA do not follow the most 
highly endorsed of the OARSI (Osteoarthritis Research Society International) 
recommendations for management of OA. Health professionals should be 
encouraged to recommend evidence-based therapies to their patients. 
 
 (243 words) 
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Introduction 
Osteoarthritis (OA) is the most common form of musculoskeletal disorder [1] and a 
leading cause of pain and disability in most Western developed countries [2,3]. The 
prevalence and incidence of OA increases with age, and with the aging of 
populations, both prevalence and incidence are expected to rise. Significant planning 
will thus be required to cope with the growing burden of this disease and its impact 
on health services.  
Osteoarthritis is a degenerative musculoskeletal condition, which can cause 
pain, stiffness, disability and deformity [4]. People with OA typically have pain that 
worsens with weight-bearing activities [5]. Therefore, the goals for management are 
to reduce joint pain and stiffness, maintain and improve joint mobility, improve 
muscle strength, limit subsequent joint damage, reduce activity limitations, and 
improve health-related quality of life [5-7]. Management can include non-
pharmacological and pharmacological therapies, with surgical options available for 
those who fail to respond to these therapies [8].  
Over the last decade, several evidence-based recommendations have been 
made for the management of hip and knee OA [8-11]. These include both non-
pharmacological and pharmacological therapies. In the most recent review of the 
evidence by Osteoarthritis Research Society International (OARSI) [8], education, 
exercise, patient contact by telephone and provision of walking aids were the most 
highly recommended non-pharmacological therapies, and acetaminophen, non-
selective nonsteriodal anti-inflammatory drugs (NSAIDS), opioids and some herbal 
remedies were the most highly recommended pharmacological therapies. Other 
therapies have not undergone the same level of rigorous evaluation as these and 
thus could not be highly recommended. 
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Although evidence supports certain therapies for OA management, little is 
known about which therapies are actually being used by people with OA.  In 
reviewing the literature on therapy use, Li et al. [12] found that researchers have 
tended to ask physicians to report their patients’ use of therapies, rather than asking 
patients directly.  Only three studies have asked OA patients themselves. These 
studies found that exercise, walking sticks or other aids, physical therapy, analgesics 
and NSAIDS were the most commonly-used therapies [12-14].  However, the range 
of therapies examined was narrow and did not reflect current recommendations for 
the management of hip or knee OA.  
Some studies have specifically investigated patterns of health care utilisation 
[15-17]. Hopman-Rock et al. found that 82% of elderly people with hip or knee pain 
consulted a general practitioner (GP) and more than half saw a physiotherapist. 
Other studies, however, have found that the percentage of OA sufferers who seek 
help from general practitioners or primary care physicians varies enormously (25- 
92%) while the percentage who seek advice from OA specialists and other allied 
health professionals tends to be lower, though similar, across these studies (3-25%). 
These differences in health care utilisation rates may reflect differences across 
studies, including different time frames for help-seeking behaviour between GPs and 
allied health professionals, sampling techniques, health care systems and health 
insurance systems. These studies did not report the pattern of utilisation of other 
common non-pharmacological and pharmacological therapies.  
Little is also known about differences between men and women in their use of 
therapies to treat of OA. However, findings from previous studies indicate that 
differences may exist. Data from a recent study suggest that women with arthritis are 
2.5 times more likely than men to seek help from alternative therapists, such as 
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homeopaths, acupuncturists, osteopaths, aromatherapists and chiropractors [16]. 
This finding is consistent with previous studies looking at complementary and 
alternative medicine use among adults [18-20]. Theis et al. found that, when given 
advice by a healthcare provider, more women than men in the US exercise and try to 
lose weight to improve their OA symptoms [20]. This gender disparity in managing 
OA symptoms may similarly persist with the use of other non-pharmacological and 
pharmacological therapies.  
The primary aims of this study were to identify which of 32 common non-
pharmacological and pharmacological therapies were being used for the 
management of hip or knee OA in a community-based sample of adults living in 
Brisbane, Australia, and to compare use of these therapies with current OARSI 
evidence-based recommendations. The secondary aim was to compare the use of 
these therapies in men and women, as it was hypothesised that choice of therapies 
would differ between men and women. 
Methods 
Sampling and Study Protocol 
A mail questionnaire was used to collect descriptive data from adults with hip or knee 
OA who were living in Brisbane, Australia. The sample was drawn from the 
membership database of Arthritis Queensland, which is a non-profit organisation that 
provides support and resources for people with arthritis. Members listed in the 
database as having OA and living within a 100-km radius of Brisbane were eligible to 
participate.  
Questionnaire packets were mailed in two waves. For the first wave, the 
packet was mailed by Arthritis Queensland to the 600 women most recently added to 
their database, who lived in Brisbane and neighbouring communities, and to all male 
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members living in the same areas.  A second wave was conducted 4 months later by 
sending the packet to an additional 500 men and 500 women, who lived in the next 
closest communities. Again, the newest Arthritis Queensland members living in 
these communities were selected. Questionnaires were mailed with an invitation 
letter and a self-addressed reply-paid envelope. Three weeks after receiving this 
mailing, participants were sent a reminder letter. Questionnaire completion 
designated informed consent. The study was approved by the University of 
Queensland Medical Research Ethics Committee. 
The Analysis Sample 
Participants were included in these analyses if, on the questionnaire, they reported 
their sex, and the date of their OA diagnosis (in the last year, 2-3 years ago, 4-5 
years ago, more than 5 years ago). They also had to indicate that they had either 
knee or hip OA. 
Measures 
Demographic and Health-Related Characteristics. The questionnaire included 
questions about sex, age, country of birth (a measure of ethnicity), marital status, 
highest educational qualification, employment status, main lifetime occupation, 
height and weight. Self-reported body mass index (weight [kg] / height [m2]) was 
categorized as normal-range weight (<25), overweight (25 to <30), or obese (≥30), in 
accordance with World Health Organization guidelines [21]. Participants were also 
asked whether they had been told by a doctor in the previous 3 years that they had 
any other chronic conditions, from a list adapted from the Australian 1989–1990 
National Health Survey [22]. Chronic conditions included heart diseases, low iron 
level, asthma, osteoporosis, cancer and Alzheimer’s Disease or dementia. 
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Arthritis Symptoms. The 24-item WOMAC Osteoarthritis Index Likert 3.1 was used 
to measure participants’ symptoms of hip or knee OA. The scale includes pain (5 
items), stiffness (2 items), and physical function (17 items) subscales. For each 
subscale, response categories are on a Likert scale (1 = none, 2 = mild, 3 = 
moderate, 4 = severe and 5 = extreme). Subscale items were summed to create 
subscale scores, with higher scores indicating worse symptoms (i.e., more pain, 
stiffness, or difficulty with daily activities, respectively). All items were summed to 
create a total index score, with possible values ranging from 24 to 120. The index 
has been extensively validated in people with knee or hip OA and is one of the main 
self-report measures of OA symptoms being used internationally [23,24]. 
Therapies for Managing Osteoarthritis Symptoms. Participants were asked to 
report their use of 21 non-pharmacological therapies and 11 pharmacological 
therapies for managing their OA symptoms. The selected therapies were ones 
commonly reported in the scientific literature for OA management [9-12,25,26], and 
are listed in Tables 3 and 4.  
For each therapy, participants were asked to report the frequency of their use 
by indicating ‘no, never tried’; ‘yes, take as needed’; ‘yes, usually take 1-3 days per 
week’; ‘yes, usually take 4-6 days per week’; or ‘yes, usually take every day’. Based 
on the distribution of responses, responses were categorised as ‘never tried’, 
‘infrequent use’ (<4 days/week) and ‘frequent use’ (≥4 days/week). For 
pharmacological therapies with very low usage rates (i.e., steroid injections, oral 
corticosteroids, hylauronan injections and opiod oral medications), the ‘infrequent’ 
and ‘frequent’ categories were combined for analysis to represent ‘any use’.  
The therapies listed in the tables were compared with the OARSI 
recommendations when applicable, as not all of the therapies mentioned in the study 
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have been recommended by OARSI. The strength of recommendation (SOR) for 
OARSI recommendation are based on the opinions and clinical expertise of the 
Guideline Development Group, considering research evidence for safety, efficacy, 
cost-effectiveness, patient tolerance, acceptability and adherence [6].  
Statistical Analysis 
Descriptive statistics were computed for all study variables, separately for men and 
women. To compare men and women, the independent sample t-test was used for 
continuous variables (WOMAC scores) and the chi-square test was used for most 
categorical variables (demographic and health-related characteristics and some 
therapies). The Fisher’s Exact test was used for non-pharmacological and 
pharmacological therapies in which usage rates were low. For non-pharmacological 
therapies with low use (low level laser therapy and viscosupplementation), the 
percentages of men and women who ‘never tried’ were compared with those 
‘currently using’ these therapies. Participants who reported that they had stopped 
using these therapies were not included, so that the analyses focused on current 
users.  For pharmacological therapies with low use (steroid injections, oral 
corticosteroids, hyaluronan injections and opioid oral medication), any use 
(‘infrequent’ or ‘frequent’) was compared with no use.  
Results 
Description of the Sample 
As shown in Figure 1, 2200 Arthritis Queensland members were mailed the 
questionnaire packet. Of the 658 who returned completed questionnaires (31% 
response rate), 80% reported hip or knee OA. Fifteen of these participants were 
excluded because they did not report their sex, and another 26 were excluded 
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because they did not indicate years since their diagnosis of OA. Thus, data from 192 
men and 293 women were included in these analyses. 
INSERT FIGURE 1 APPROXIMATELY HERE 
Demographic and health characteristics of the sample are presented in Table 
1. Although equal numbers of questionnaires were mailed to men and women, 60% 
of the analysis sample was women. The age range of participants was 27-95 years; 
more men than women were aged ≥75 years (p=.001). More men than women listed 
their main lifetime occupation as manager or professional (p=.001), and reported 
having heart disease (p<.001) or cancer (p=.002) whereas more women reported 
having a low iron level (p=.04), asthma (p<.001), osteoporosis (p<.001) or 
Alzheimer’s Disease or dementia (p=.04). There was no sex difference in time since 
diagnosis.  
INSERT TABLE 1 APPROXIMATELY HERE 
Mean WOMAC scores for both men and women indicated mild to moderate 
symptoms of hip or knee OA, on average. Mean scores for men and women were 
not statistically different (See Table 2). 
INSERT TABLE 2 APPROXIMATELY HERE 
Overall, 96% of participants reported using at least one non-pharmacological 
therapy for managing their OA; these are presented in Table 3, listed in order of 
SOR, for comparison with recommendations.  
The most commonly reported management strategies were making efforts to 
lose weight, using range of motion, and performing muscle strengthening exercises; 
each was reported by more than half the participants. Wearing shoes with shock-
absorbing properties or orthoses; applying heat or cold treatments; using objects to 
help with daily living; taking information and education courses; and using herbal 
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therapies, such as celery seeds, ginger, and willow bark, were less popular. Most 
participants reported that they had never tried low level laser therapy, 
viscosupplementation, phone counselling, occupational therapy, taping, 
transcutaneous electrical nerve stimulation, or mega-vitamin therapy to manage their 
OA symptoms.   
There were statistically significant differences in the proportions of men and 
women using 11 of the 21 non-pharmacological therapies. In pairwise comparisons 
between participants who were current users of a therapy and participants who had 
never tried the therapy, more women than men were found to be currently attending 
information courses (p=.015), performing range of motion exercises (p=.020), or 
taking aerobic exercise classes (p=.007). More women than men were also currently 
using shoes with shock absorbing properties or orthotics (p=.002), objects to help 
with daily living (p=.001), hydrotherapy (p<.001), or heat or cold treatments (p<.001). 
More men than women, however, were currently taping their patella (p=.014). 
INSERT TABLE 3 APPROXIMATELY HERE 
Overall, 78% of participants used at least one pharmacological therapy, as 
shown in Table 4, listed in order of SOR. The most popular therapies were 
glucosamine or chondroitin and anti-inflammatory tablets or capsules. The 
proportions using paracetamol, paracetamol-plus-codeine and topical anti-
inflammatory gels and creams 'frequently' were low, but high percentages of 
participants reported using these therapies infrequently (less than 4 days per week; 
see Table 4). Most participants reported that they had never tried hyaluronan 
injections, opioid oral medications, oral corticosteroids, steroid injections or tramadol, 
for managing OA symptoms. 
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There were few sex differences in the use of these pharmaceutical therapies.. 
In pairwise comparisons between participants who were current users of a therapy 
and participants who were not using the therapy, more women than men reported 
using anti-inflammatory capsules or tablets (p=.009), paracetamol-only medications 
(p=.015), or steroid injections (p=.010), for management of OA symptoms.  
INSERT TABLE 4 APPROXIMATELY HERE 
Discussion 
To our knowledge, this study was the first to examine the use of non-
pharmacological and pharmacological therapies for management of OA in a 
community sample of people with mild to moderate symptoms of hip or knee OA. 
The most commonly reported non-pharmacological therapies were making efforts to 
lose weight and participation in range of motion and muscle strengthening exercises, 
while the most common pharmacological therapy was glucosamine and/or 
chondroitin; each of these strategies was reported by more than half of participants 
in this study. 
 The highest endorsement from OARSI (SOR=97%) for non-pharmacological 
management of OA is for patients to attend an information or education course, so 
that they can self-manage their condition.  Significantly more women than men were 
currently attending a course. However, more than two thirds of the men (65%) and 
just over half the women (54%) had never done this. This may reflect the lack of 
awareness or availability of formal self-help pain management courses.  
The second most highly rated strategy for relieving pain and reducing activity 
limitations among people with hip and knee OA is weight loss, with SOR=96% 
[6,27,28]. In the current study, almost two thirds (59%) of participants were making 
efforts to lose weight. This is much higher than in a 2004 study, in which only one 
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third (35%) of participants were trying to lose weight for the management of OA [12]. 
This difference may reflect differences in the weight status of participants, or in 
health professionals’ recommendations, in the communities in which the two studies 
were based. In the present study, similar percentages of women and men were 
overweight or obese, and similar proportions were making efforts to lose weight, 
which is surprising, as there is a general tendency for women to be more concerned 
about their weight then men [29]. Findings from the United States National Health 
Interview Survey (NHIS) revealed that more women (42%) than men (32%) are 
advised by a doctor or other health professional to lose weight to improve their 
symptoms [30].  
The finding that most participants reported using some form of exercise (78% 
doing strength training, stretching, or aerobic exercise classes) supports the high 
recommendation for this strategy (SOR 96%), which is based on evidence that 
shows improvements in pain, physical function and stiffness with exercise [31-34].   
Li et al. [12] also reported that exercise was the most popular non-pharmacological 
therapy for OA management, with 73% of participants reporting that they had tried 
exercising at home or in a group, with most continuing to exercise. Data on the types 
of exercises that participants were doing were not reported for that study.  In 
contrast, Tallon et al. [14] reported that physical therapy (e.g., physiotherapy, 
exercise, and chiropractic combined) was the third most frequently used therapy for 
people with knee OA, although only 16% of participants were using this therapy 
frequently. Exercise participation other than physical therapy was not addressed in 
that study. In summary, our findings, supported with those from Li et al. [12], indicate 
that a large percentage of people with mild to moderate symptoms of hip or knee OA 
are exercising to manage their OA, although neither the current study nor previous 
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studies provide information on the frequency and duration of the exercise being 
performed for OA management. The finding that more women than men reported 
attending aerobic exercise classes and doing range of motion exercises may reflect 
the fact that women in general are much more likely than men to report these 
activities [35]. In addition, findings from the NHIS suggest that women with arthritis 
are more likely than their male counterparts to heed advice from a health 
professional and modify their behaviour to improve symptoms. Therefore, women 
receiving exercise prescription from allied professionals are more likely to exercise 
[21].    
The use of walking aids to reduce OA-related pain is also highly 
recommended by OARSI (SOR=90%). However, in this study only a quarter of 
participants reported using a stick, cane or walking frame. This proportion was a little 
lower than has been reported in previous studies. Tallon et al. [14] found that 27% of 
their knee OA patients used aids (such as canes, braces, and bath or stair rails), and 
Li et al. [12] reported that 31% of OA patients had ever tried mobility aids (such as 
canes, crutches or walkers).These differences may reflect a lower severity of OA 
symptoms among participants in our study than among participants in earlier studies. 
No significance differences were found in the proportion of men and women using 
walking aids. 
Novel non-pharmacological therapies such as acupuncture (OARSI rating: 
SOR-59%) and TENS (OARSI rating: SOR=58%) are included in the OARSI 
guidelines [6] but do not receive the strong recommendations given to weight loss or 
exercise, due to the small number of high quality randomised controlled trials to 
assess their effectiveness. It was not surprising that most participants in the current 
study reported they had never tried acupuncture (67%) or TENS (75%), given the 
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novelty of these therapies and thus likely low availability in the local area. There 
were no significance differences in the proportion of men and women using 
acupuncture and TENS. 
For pharmacological management of OA symptoms, the highest OARSI 
recommendation is for anti-inflammatory tablets or capsules for short-term pain relief 
(SOR=93%) and paracetamol for long-term relief (SOR=92%).  However, in this 
study, the most common frequently used pharmacological strategy was 
glucosamine/chondroitin (SOR=63%), which was reported by 57% of participants.  
The lower SOR for glucosamine/chondroitin therapy (than for NSAIDS and 
paracetamol) is due to controversy over whether glucosamine and chondroitin act as 
symptom-modifying drugs [8]. Nonetheless, reviews of OA therapies [36-39] indicate 
that both therapies are well-tolerated and have positive effects on joint space 
narrowing, pain and physical function.  In contrast with our findings, Jordan et al. [13] 
reported that few participants with knee OA were taking these medicines: only 16% 
were taking glucosamine and 5% were taking chondroitin.  These differences may 
reflect local differences in availability, marketing and promotion of these 
complementary medicines. There were no significance differences in the proportion 
of men and women taking glucosamine and chondroitin. 
Anti-inflammatory medications were the second most popular 
pharmacological therapy taken frequently (at least 4 days/week): this was reported 
by 44% of participants. The analgesic paracetamol (acetaminophen) with or without 
codeine was popular for infrequent use (<4 days/week), but not frequent use: 21% 
took this analgesic frequently but 49% took it infrequently. Tallon et al. [14] reported 
that simple analgesics and anti-inflammatory drugs (which were assessed together) 
were the most commonly-used therapies among participants with knee OA: 53% 
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reported taking these medications ‘often’ or ‘very often’. In another study of patients 
with knee OA [13], 46% of participants reported taking NSAIDS and 43% reported 
taking paracetamol. Significantly more women than men in our study reported using 
anti-inflammatory medications. 
The main limitation of this study was the response rate (31%), which was 
much lower than in a survey of a community-based sample of Dutch people with 
rheumatoid arthritis (63%) [40]. Our participants may not therefore be representative 
of the larger osteoarthritic population, and caution should be taken in generalising 
these findings to other communities. Nonetheless, comparisons with national data 
indicate that our sample was fairly representative of people with OA nationally.  
The proportion of men in our sample (40%) was similar to the proportion of 
Australia men with self-reported medically-diagnosed OA (39%).  Our sample was 
however older (30% aged ≥75 years) than nationally-representative samples of 
people with OA (21%) [3].  This reflects the older age of the men, which may in turn, 
explain some of the observed sex differences in the use of non-pharmacological 
therapies; for example, older people may be less likely to attend an exercise class.  
However, the proportions of men who had NEVER tried each strategy were in almost 
all cases higher than the proportion of women. This finding, and the fact that there 
was no sex difference in time of diagnosis, or in WOMAC scores, suggests that the 
age difference may not entirely explain the observed sex differences in management 
strategies.  
In contrast with a recent survey, which found that 36% of people with arthritis 
report taking actions for their condition [41], almost all the participants in our sample 
reported using therapies to manage their OA symptoms. This large proportion 
probably reflects the fact that our participants were members of Arthritis Queensland 
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(AQ), which provides support for people with OA.  The participants had previously 
reported to AQ that they had OA, and specified on their completed questionnaire that 
they had OA of the hip or knee.  Their WOMAC scores indicate, however, that, on 
average, participants had mild to moderate symptoms of OA, and this may be 
reflected in the management strategies reported here. 
Another limitation is the crude categorical measures of therapy use, which, 
given the distribution of the data, were created to designate current and past use and 
frequency of use.  While detailed descriptions of duration and frequency of use could 
not be examined, the categories used were similar to those in previous studies. As in 
all questionnaires, we relied on self-reported data on OA diagnosis and management 
strategies.  The therapies selected for inclusion in this study were based on common 
therapies reported in scientific literature for OA management [9-12,25,26].  The 
comparison of our results with the OARSI recommendations must therefore be 
cautiously interpreted, especially as practice patterns, regulations, availabiltiy and 
reimburesment policies are likely to vary in different countries, and to affect 
compliance with OARSI recommendations [42].  
Despite these limitations, the study has important implications for health 
professionals, researchers and health promotion practitioners.  Health professionals 
may find it helpful to understand which therapies are commonly adopted by men and 
women with OA, and which of those recommended by OARSI (such as exercise and 
paracetamol) should be more widely recommended to patients. Researchers who 
are interested in assessing the efficacy of specific therapies may find it helpful to 
understand the range of therapies currently being utilised, so that synergistic use of 
both non-pharmaceutical and pharmaceutical therapies can be considered in future 
interventions.  Future research should also confirm the sex-differences in 
18 
 
management strategies reported here.  Health promotion practitioners may be 
interested to know that few people with OA attend education courses.  This may be 
an issue of access, availability or marketing.   
In conclusion, the results show that in this Australian sample, people with OA 
follow some, but not all, the OARSI recommendations for the management of this 
chronic condition.  Strategies, such as attending an education course, weight loss, 
exercise (especially for men), and paracetamol (for long-term pain relief) could be 
more widely recommended. 
 
3907 words 
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Table 1:  Demographic and health-related characteristics of the sample (N = 
485) 
 Characteristics   
Gender 
comparison 
 Men Women X2# p-value 
 n (%) n (%)   
Sex 192 (39.6) 293 (60.4)   
     
Age (years)     
< 65 60 (31.3) 118 (40.3)   
65 – 74 58 (30.2) 104 (35.5)   
≥75 74 (38.5) 71 (24.2) 11.49 0.003 
     
Country of birth      
Australia  141 (73.4) 219 (74.7)   
Other country 51 (26.6) 74 (25.3) 0.10 0.75 
     
Marital status     
Married or common-law relationship 138 (71.9) 176 (60.1)   
Never married, separated or divorced 29 (15.1) 61 (20.8)   
Widowed 25 (13.0) 56 (19.1) 7.12 0.03 
     
Qualifications     
No high school diploma 52 (27.1) 140 (47.8)   
High school diploma 31 (16.1) 48 (16.4)   
Trade/apprenticeship, certificate/diploma 70 (36.5) 57 (19.5)   
University degree 39 (20.3) 48 (16.4) 26.36 <0.001 
     
Employment status     
Employed for pay 47 (24.5) 58 (19.8)   
Not employed for pay/retired 145 (75.5) 235 (80.2) 1.50 0.26 
     
Main previous or current occupation      
Manager or professional 75 (39.1) 73 (24.9)   
Tradesperson or clerical worker 56 (29.2) 111 (37.9)   
Transport, sales, service worker or labourer 42 (21.9) 37 (12.6)   
No paid job 19 (9.9) 72 (24.6) 29.58 <0.001 
     
BMI      
Normal (BMI < 25) 50 (26.0) 95 (32.4)   
Overweight (BMI 25 to < 30)  86 (44.8) 116 (39.6)   
Obese (BMI > 30) 56 (29.2) 82 (28.0) 2.39 0.30 
     
Heart disease     
Yes  49 (25.5) 45 (15.4)   
No 143 (74.5) 248 (84.6) 7.67 <0.001 
     
Low iron level     
Yes  22 (11.5) 54 (18.4)   
No 170 (88.5) 239 (81.6) 4.27 0.04 
     
Asthma     
Yes  20 (10.4) 77 (26.3)   
No 172 (89.6) 216 (73.7) 18.24 <0.001 
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Osteoporosis     
Yes  24 (12.5) 91 (31.1)   
No 168 (87.5) 202 (68.9) 22.08 <0.001 
Cancer     
Yes  28 (14.6) 17 (5.8)   
No 164 (85.4) 276 (94.2) 10.63 0.002 
     
Alzheimer’s Disease or Dementia     
Yes   5 (2.6) 1 (0.3)   
No 187 (97.4) 292 (99.7) 4.86 a 0.04 
     
Time of OA diagnosis      
In the last year  12 (6.3) 17 (5.8)   
2-3 years ago 21 (10.9) 45 (15.4)   
4-5 years ago 30 (15.6) 35 (11.9)   
More than 5 years ago 129 (67.2) 196 (66.9) 2.88 0.41 
     
# Pearson’s Chi-Square Test is reported unless noted. 
a Fisher’s Exact Test statistic is reported. 
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Table 2.  Men’s and women’s WOMAC scores, as measures of 
osteoarthritis symptoms (N = 485) 
 Men 
n = 192 
Women 
n = 293 
WOMAC Index Mean 95% CI Mean 95% CI 
Total Index score 53.56 50.18-56.95 55.11 52.33-57.88 
Pain 11.33 10.60-12.07 11.47 10.87-12.07 
Stiffness 4.62 4.30-4.94 4.95 4.68-5.21 
Physical function 37.61 35.14-40.09 38.69 36.66-40.72 
Note. Higher scores indicate worse symptoms. No statistically significant differences were found between men 
and women for any WOMAC score (p>.05). 
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Table 3:  Current recommendations (based on SOR) for non-pharmacological management of hip and knee OA and 
current use of therapies in men and women with mild to moderate OA (N = 485) 
 
  Men (n = 192) Women (n = 293) Gender comparison 
 SOR* (%) (95%) 
Never 
tried 
n  (%) 
Stopped 
using 
n (%) 
Currently 
using 
n  (%) 
Never 
tried 
n  (%) 
Stopped 
using 
n  (%) 
Currently 
using 
n  (%) 
X2# p-value 
          
Information/education 
course 
(e.g. self-management 
program) 
97 (95-99) 124 (64.6) 24 (12.5) 44 (22.9) 157 (53.6) 40 (13.7) 96 (32.8) 6.44 0.04 
          
Making efforts to lose 
weight 96 (92-100) 72 (37.5) 9 (4.7) 111 (57.8) 97 (33.1) 22 (7.5) 174 (59.4) 2.14 0.34 
          
Aerobics exercise class 96 (93-99)c 159 (82.8) 19 (9.9) 14 (7.3) 174 (59.4) 81 (27.6) 38 (13.0) 30.48 <0.001 
          
Range of motion exercises  
(stretching exercises)  96 (93-99)
c 68 (35.4) 24 (12.5) 100 (52.1) 73 (24.9) 43 (14.7) 177 (60.4) 6.21 0.05 
          
Muscle strengthening 
exercises 96 (93-99)
c 75 (39.1) 28 (14.6) 89 (46.4) 99 (33.8) 37 (12.6) 157 (53.6) 2.43 0.30 
          
A walking stick, cane, 
walker, or other objects to 
help with walking 
90 (84-96) 119 (62.0) 26 (13.5) 47 (24.5) 192 (65.5) 34 (11.6) 67 (22.9) 0.71 0.70 
          
Occupational therapy 89 (82-96) 166 (86.5) 18 (9.4) 8 (4.2) 246 (84.0) 20 (6.8) 27 (9.2) 5.14 0.08 
          
Shoes with shock-
absorbing properties or 
orthoses in your shoes 
77 (66-88) 116 (60.4) 12 (6.3) 64 (33.3) 139 (47.4) 11 (3.8) 143 (48.8) 11.74 0.003 
          
Taping of the knee patellar 76 (69-83) 151 (78.6) 19 (9.9) 22 (11.5) 244 (83.3) 34 (11.6) 15 (5.1) 6.72 0.04 
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Getting counselling over 
the phone 66 (57-75) 180 (93.8) 7 (3.6) 5 (2.6) 262 (89.4) 18 (6.1) 13 (4.4) 2.69 0.26 
          
Heat/cold treatment 64 (60-68) 109 (56.8) 36 (18.8) 47 (24.5) 114 (38.9) 53 (18.1) 126 (43.0) 19.27 <0.001 
          
Acupuncture  59 (47-71) 138 (71.9) 47 (24.5) 7 (3.6) 187 (58.7) 86 (29.4) 20 (6.8) 4.23 0.12 
          
Transcutaneous electrical 
nerve stimulation (TENS) 58 (45-72) 144 (75.0) 35 (18.2) 13 (6.8) 218 (74.4) 48 (16.4) 27 (9.2) 1.08 0.58 
          
Objects to help with daily 
living (e.g. sock aids, zipper 
pulls, jar openers) 
NR 141 (73.4) 8 (4.2) 43 (22.4) 174 (59.4) 13 (4.4) 106 (36.2) 10.72 0.01 
          
Low level laser therapy 
(LLLT) NR 186 (96.9) 5 (2.6) 1 (0.5) 281 (95.9) 8 (2.7) 4 (1.4) 0.81
b 0.65 
          
Any herbal therapies such 
as celery seeds, ginger, 
willow bark etc. 
NR 118 (61.5) 29 (15.1) 45 (23.4) 171 (58.4) 38 (13.0) 84 (28.7) 1.76 0.41 
          
Megavitamin therapy NR 150 (78.1) 12 (6.3) 30 (15.6) 207 (70.6) 16 (5.5) 70 (23.9) 4.85 0.09 
          
Viscosupplementation  NR 180 (93.8) 10 (5.2) 2 (1.0) 277 (94.5) 7 (2.4) 9 (3.1) 2.03b 0.22 
          
Hydrotherapy (warm water 
exercises) NR 141 (73.4) 33 (17.2) 18 (9.4) 152 (51.9) 78 (26.6) 63 (21.5) 23.65 <0.001 
          
Massage therapy (e.g. 
acupressure, shiatsu) NR 137 (71.4) 34 (17.7) 21 (10.9) 201 (68.6) 39 (13.3) 53 (18.1) 5.50 0.06 
          
Magnet therapy NR 121 (63.0) 39 (20.3) 32 (16.7) 172 (58.7) 60 (20.5) 61 (20.8) 1.40 0.50 
          
* SOR (Strength of recommendation derived from OARSI recommendations) 
# Pearson’s Chi-Square statistic is reported unless noted. 
 b Fisher’s Exact Test statistic is reported. Comparisons were made between ‘never tried’ and ‘currently using’ a therapy.  
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C OARSI groups these therapies into one recommendation. 
NR Not an OARSI recommendation. 
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Table 4:  Current recommendations (based on SOR) for pharmacological management of hip and knee OA and 
current use of therapies in men and women with mild to moderate OA (N = 485) 
 
 
 
Men (N = 192) Women (N = 293)  
Group 
compari
son 
 SOR* (%)
(95%)
Not using
n  (%) 
Infrequent
n  (%) 
Frequent
n  (%) 
Not using
n  (%) 
Infrequent
n  (%) 
Frequent
n  (%) X
2# p-value 
   
Anti-inflammatory 
tablets or capsules 93 (88-99) 58 (30.2) 54 (28.1) 80 (41.7) 58 (19.8) 100 (34.1) 135 (46.1) 7.08 0.03 
          
Paracetamol only  92 (88-99)c 70 (36.5) 86 (44.8) 36 (18.8) 76 (25.9) 153 (52.2) 64 (21.8) 6.10 0.05 
          
Paracetamol plus 
codeine combinations 92 (88-99)
c 116 (60.4) 59 (30.7) 17 (8.9) 174 (59.4) 97 (33.1) 22 (7.5) 0.49 0.78 
          
Topical anti-
inflammatory gels or 
creams 
85 (75-95) 120 (62.5) 59 (30.7) 13 (6.8) 154 (52.6) 120 (41.0) 19 (6.5) 5.33 0.70 
          
Opioid oral medication  82 (74-90) c 180 (93.8) 8 (4.2) 4 (2.1) 277 (94.5) 4 (1.4) 12 (4.1) 0.13 d 0.70 
          
Tramadol 82 (74-90) c 171 (89.1) 13 (6.8) 8 (4.2) 260 (88.7) 19 (6.5) 14 (4.8) 0.11 0.95 
          
Steroid injections 78 (61-95) 168 (87.5) 24. (12.5) 0 (0.0) 226 (77.1) 65 (22.2) 2 (0.7) 8.18 d 0.01 
          
Hyaluronan injections 64 (43-85) 190 (99.0) 2 (1.0) 0 (0.0) 289 (98.6) 2 (0.7) 2 (0.7) 0.10 d 1.00 
          
Glucosamine or 
Chondroitin  63 (44-82) 72 (37.5) 22 (11.5) 98 (51.0) 88 (30.0) 29 (9.9) 176 (60.1) 3.90 0.14 
          
Oral corticosteroids  NR 179 ( 93.2) 8 (4.2) 5 (2.6) 274 (93.5) 15 (5.1) 4 (1.4) 0.02 d 1.00 
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Topical liniment rubs NR 85 (44.3) 87 (45.3) 20 (10.4) 134 (45.7) 144 (49.1) 15 (5.1) 4.92 0.09 
   
* SOR (Strength of recommendation derived from OARSI recommendations) 
# Pearson’s Chi-Square statistic is reported unless noted. 
C OARSI groups these therapies into one recommendation. 
d Fisher’s Exact Test statistic is reported. Comparisons were made between ‘Infrequent’ and ‘frequent’ use of pharmacological therapy.  
NR Not an OARSI recommendation. 
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Figure 1:  Summary of the recruitment process 
First mail out of 
1200 questionnaire packs 
3 weeks later  
Postcard reminders sent 
417 individuals completed the questionnaire 
35% response rate 
A total of 658 individuals  
completed the questionnaire 
31% response rate  
485 individuals  
with osteoarthritic symptoms of the knee and hip 
Second mail out of 
1000 questionnaire packs 
3 weeks later  
Postcard reminders sent 
241 additional individuals completed the questionnaire 
24% response rate 
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